The concept of personalised medicine is becoming established in cancer, with an increasing number of drugs targeting specific mutations making it to market.
Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still.
With genetic analysis and diagnostic tests now available via mail order, how will this trend towards the proactive consumer impact the evolution of health management?